StemCell Institute AI Stock Analysis
Want to see JP:7096 full AI Analyst Report?
StemCell Institute (7096) AI Stock Analysis
StemCell Institute
(TSE/TYO:7096)
The score is primarily held back by deteriorating cash flow and a sharp 2026 profitability decline, despite steady revenue growth and a generally healthy balance sheet. Technicals add further pressure with the stock trading below all major moving averages and negative MACD. A high P/E with no dividend support limits valuation attractiveness.
StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.43B
- Dividend Yield
- ―
- Average Volume (3M)
- 5,151
- Price to Earnings (P/E)
- 57.3
- Beta (1Y)
- 0.52
- Revenue Growth
- 2.55%
- EPS Growth
- -43.06%
- Country
- Japan
- Employees
- 117
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
StemCell Institute Business Overview & Revenue Model
Company Description
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, an...
StemCell Institute Financial Statement Overview
Summary
Mixed fundamentals: revenue growth has been steady and gross margin remains solid (~61%), and leverage is still modest (debt-to-equity ~0.18). However, profitability compressed sharply in 2026 (net margin ~5.5% vs ~14.4% in 2025) and cash flow deteriorated meaningfully with free cash flow swinging to a large deficit, raising near-term execution and funding-quality risk.
Income Statement
64PositiveBalance Sheet
72PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.81B | 2.81B | 2.68B | 2.48B | 2.09B | 1.78B |
| Gross Profit | 1.71B | 1.71B | 1.69B | 1.58B | 1.34B | 1.11B |
| EBITDA | 368.87M | 379.99M | 695.19M | 534.00M | 402.49M | 309.47M |
| Net Income | 153.86M | 155.92M | 385.80M | 310.98M | 198.03M | 133.73M |
Balance Sheet | ||||||
| Total Assets | 8.12B | 8.12B | 7.52B | 6.59B | 5.83B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 2.83B | 3.20B | 2.85B | 3.32B | 3.51B |
| Total Debt | 473.81M | 473.81M | 518.96M | 10.78M | 5.89M | 0 |
| Total Liabilities | 5.05B | 5.05B | 4.89B | 3.90B | 3.53B | 3.13B |
| Stockholders Equity | 2.68B | 2.68B | 2.63B | 2.69B | 2.30B | 2.10B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -335.78M | -10.11M | 132.97M | 39.77M | 264.81M |
| Operating Cash Flow | 0 | 73.51M | 467.69M | 334.63M | 99.67M | 469.29M |
| Investing Cash Flow | 0 | -337.92M | -259.08M | -811.77M | -285.10M | 404.17M |
| Financing Cash Flow | 0 | -175.09M | 146.70M | -1.33M | -869.00K | 644.37M |
StemCell Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 643.00 is below the 20-day moving average (MA) of 679.85, below the 50-day MA of 716.98, and below the 200-day MA of 749.41, indicating a bearish trend. The MACD of -22.54 indicates Positive momentum. The RSI at 33.88 is Neutral, neither overbought nor oversold. The STOCH value of 21.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.
StemCell Institute Peers Comparison
Overall Rating
JP:709651Neutral
JP:497842Neutral
JP:777442Neutral
JP:459938Underperform
JP:459337Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | JPY 6.59B | 57.28 | ― | ― | 2.55% | -43.06% | |
| 42Neutral | JPY 11.33B | -23.68 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 25.58B | -69.38 | ― | ― | 17.05% | 10.47% | |
| 38Underperform | JPY 7.90B | -4.21 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 27.92B | -12.37 | ― | ― | -51.55% | 52.19% | |
| 37Underperform | JPY 6.11B | -4.70 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7096 | StemCell Institute | 643.00 | -113.00 | -14.95% | |
| JP:4593 | Healios KK | 206.00 | -280.00 | -57.61% | |
| JP:4599 | StemRIM Inc. | 126.00 | -151.00 | -54.51% | |
| JP:4978 | ReproCELL Inc. | 105.00 | -55.00 | -34.38% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 630.00 | 151.00 | 31.52% | |
| JP:7776 | CellSeed Inc. | 154.00 | -225.00 | -59.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
